SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 31, 2002
Arrhythmia Research Technology, Inc.
(Exact name of issuer as specified in its charter)
Delaware 1-9731 72-0925679
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification Number)
25 Sawyer Passway
Fitchburg, MA 01420
(Address of principal executive offices and zip code)
(978) 345-5000
(Registrant's telephone number, including area code)
Item 5. Other Events
On September 27, 2002 Arrhythmia Research Technology, Inc. (the
"Company") issued a press release announcing that Vice President of Finance and
Chief Financial Officer Richard A. Campbell resigned his position with the
Company effective August 31, 2002, for personal reasons. The Company is
proceeding diligently to fill the position of Chief Financial Officer. Pending
the hiring of a new Chief Financial Officer, the Company's President, with the
assistance of the Company's accounting staff and outside advisors, has assumed
the Chief Financial Officer function.
Forward looking statements made herein are based on current
expectations of the Company that involve a number of risks and uncertainties and
should not be considered as guarantees of future performance. These statements
are made under the Safe Harbor Provisions of the Private Securities Litigation
Reform Act of 1995. The factors that could cause actual results to differ
materially include: the ability of the Company to engage a new Chief Financial
Officer in a timely manner, interruptions or cancellations of existing
contracts, impact of competitive products and pricing, product demand and market
acceptance and risk, the presence of competitors with greater financial
resources than the Company, product development and commercialization risks and
an inability to arrange additional debt or equity financing.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
The press release of the registrant is attached as Exhibit 99.1 to
this report.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Fitchburg, Commonwealth
of Massachusetts, on the 30th day of September, 2002.
Arrhythmia Research Technology, Inc.
/s/ James E. Rouse
-------------------------------------
President and Chief Operating Officer
Exhibit Index
Exhibit Description
99.1 Press Release dated September 27, 2002